Headache

Eptinezumab Infusions

Eptinezumab Infusions (N = 398)

2023

GAD-7 = Generalized Anxiety Disorder Questionnaire, HIT-6 = Headache Impact Test, PHQ-9 = Patient Health Questionnaire, PROMIS = Patient Reported Outcome Measurement Information System.

Eptinezumab is the first anti-CGRP drug to be administered quarterly intravenously. In February 2020, eptinezumab was approved for adult migraine treatment in the USA. In 2023, 398 headache patients were provided eptinezumab treatment and completed at least one follow-up questionnaire following the initiation of treatment. 32% of patients had improved headache impact scores.¹ PROMIS global health,² depression,³ and anxiety⁴ were stable or improved in 86% of patients or more.

References
  1. Coeytaux RR, Kaufman JS, Chao R, Mann JD, Devellis RF. Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test. J Clin Epidemiol. 2006 Apr;59(4):374-380.
  2. Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res. 2009 Sep;18(7):873-880.
  3. Löwe B, Unützer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. Med Care. 2004 Dec;42(12):1194-1201.
  4. Toussaint A, Hüsing P, Gumz A, Wingenfeld K, Harter M, Löwe B. Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7). J Affect Disord. 2020 Mar 15;265:395-401.